SK284392B6 - Analóg antracyklínu, jeho použitie a farmaceutická kompozícia na jeho báze - Google Patents

Analóg antracyklínu, jeho použitie a farmaceutická kompozícia na jeho báze Download PDF

Info

Publication number
SK284392B6
SK284392B6 SK628-98A SK62898A SK284392B6 SK 284392 B6 SK284392 B6 SK 284392B6 SK 62898 A SK62898 A SK 62898A SK 284392 B6 SK284392 B6 SK 284392B6
Authority
SK
Slovakia
Prior art keywords
trp
formula
anthracycline
anthracycline analogue
analogue
Prior art date
Application number
SK628-98A
Other languages
English (en)
Slovak (sk)
Other versions
SK62898A3 (en
Inventor
Andrew V. Schally
Attila Nagy
Ren-Zhi Cai
Original Assignee
Administrators Of The Tulane Educational Fund
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24247176&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK284392(B6) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Administrators Of The Tulane Educational Fund filed Critical Administrators Of The Tulane Educational Fund
Publication of SK62898A3 publication Critical patent/SK62898A3/sk
Publication of SK284392B6 publication Critical patent/SK284392B6/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SK628-98A 1995-11-27 1996-11-14 Analóg antracyklínu, jeho použitie a farmaceutická kompozícia na jeho báze SK284392B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/562,652 US5843903A (en) 1995-11-27 1995-11-27 Targeted cytotoxic anthracycline analogs
PCT/EP1996/005029 WO1997019954A1 (en) 1995-11-27 1996-11-14 Targeted cytotoxic anthracycline analogs

Publications (2)

Publication Number Publication Date
SK62898A3 SK62898A3 (en) 1999-06-11
SK284392B6 true SK284392B6 (sk) 2005-03-04

Family

ID=24247176

Family Applications (2)

Application Number Title Priority Date Filing Date
SK341-2004A SK284672B6 (sk) 1995-11-27 1996-11-14 Spôsob konverzie dusíka
SK628-98A SK284392B6 (sk) 1995-11-27 1996-11-14 Analóg antracyklínu, jeho použitie a farmaceutická kompozícia na jeho báze

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SK341-2004A SK284672B6 (sk) 1995-11-27 1996-11-14 Spôsob konverzie dusíka

Country Status (27)

Country Link
US (2) US5843903A (hu)
EP (2) EP1384710B1 (hu)
JP (2) JP3987575B2 (hu)
KR (2) KR100445754B1 (hu)
CN (2) CN1137136C (hu)
AT (2) ATE251179T1 (hu)
AU (1) AU709539B2 (hu)
BR (1) BR9611647B1 (hu)
CA (2) CA2471775C (hu)
CZ (1) CZ297297B6 (hu)
DE (2) DE69630233T2 (hu)
DK (2) DK1384710T3 (hu)
EA (1) EA001372B1 (hu)
ES (2) ES2310222T3 (hu)
HK (2) HK1017363A1 (hu)
HU (1) HU229870B1 (hu)
IL (3) IL134685A (hu)
IS (2) IS2178B (hu)
MX (1) MX9804119A (hu)
NO (2) NO324035B1 (hu)
NZ (1) NZ322054A (hu)
PL (3) PL188786B1 (hu)
PT (2) PT863917E (hu)
SK (2) SK284672B6 (hu)
UA (1) UA67722C2 (hu)
WO (1) WO1997019954A1 (hu)
ZA (1) ZA969709B (hu)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6576239B1 (en) 1996-09-10 2003-06-10 The Burnham Institute Angiogenic homing molecules and conjugates derived therefrom
US6180084B1 (en) 1998-08-25 2001-01-30 The Burnham Institute NGR receptor and methods of identifying tumor homing molecules that home to angiogenic vasculature using same
GB9814527D0 (en) 1998-07-03 1998-09-02 Cyclacel Ltd Delivery system
AU766489B2 (en) 1998-11-13 2003-10-16 Cyclacel Limited Transport vectors
FR2786397B1 (fr) * 1998-11-30 2003-01-10 Synt Em Vecteurs peptidiques de substances a travers la barriere hematoencephalique pour etre utilises dans le diagnostic ou la therapie d'une affection du snc
FR2786398B1 (fr) * 1998-11-30 2002-12-27 Synt Em Composition pharmaceutique anti-cancereuse et anti-chimioresistance comprenant un agent anticancereux et au moins un peptide
US6833373B1 (en) 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US6528481B1 (en) 1999-02-16 2003-03-04 The Burnam Institute NG2/HM proteoglycan-binding peptides that home to angiogenic vasculature and related methods
US6380161B1 (en) 1999-06-21 2002-04-30 Inkine Pharmaceutical Company, Inc. Compositions for treating chemotherapy-resistant tumor cells and targeted chemotherapy compositions
AU1374601A (en) * 1999-11-12 2001-05-30 Angiotech International Ag Compositions and methods for treating disease utilizing a combination of radioactive therapy and cell-cycle inhibitors
EP1242438B1 (en) 1999-12-29 2006-11-08 Immunogen, Inc. Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use
AU4267700A (en) * 2000-01-13 2001-07-19 Academia Sinica Application of somatostatin analogs to specific delivery of anti-tumor drugs into tumor cells
NZ522200A (en) * 2000-04-26 2004-07-30 Biosynthema Inc RGD (ARG-GLY-ASP) coupled to (neuro)peptides
US7452964B2 (en) 2001-09-07 2008-11-18 Board Of Regents, The University Of Texas System Compositions and methods of use of targeting peptides against placenta and adipose tissues
US20040170955A1 (en) 2000-09-08 2004-09-02 Wadih Arap Human and mouse targeting peptides identified by phage display
US7420030B2 (en) 2000-09-08 2008-09-02 The Board Of Regents Of The University Of Texas System Aminopeptidase A (APA) targeting peptides for the treatment of cancer
KR100420007B1 (ko) * 2001-04-25 2004-03-02 노영쇠 안트라사이클린 유도체 및 이를 포함하는 항암제
MXPA04002621A (es) 2001-09-21 2004-07-08 Univ Tulane Conjugados de analogos de somatostatina o bombesina para diagnostico o terapeuticos y usos de los mismos.
EP1531846A4 (en) * 2002-02-27 2006-04-19 Us Gov Health & Human Serv Conjugates of ligand, linker and cytotoxic agent and related compositions and methods of use
PL373567A1 (en) 2002-03-01 2005-09-05 The Administrators Of The Tulane Educational Fund Conjugates of therapeutic or cytotoxic agents and biologically active peptides
US7544767B2 (en) 2002-04-05 2009-06-09 Burnham Institute For Medical Research HMGN2 peptides and related molecules that selectively home to tumor blood vessels and tumor cells
BR0306685A (pt) * 2002-05-21 2005-04-26 Daiichi Suntory Pharma Co Ltd Composição farmacêutica contendo grelina
WO2003099346A2 (en) 2002-05-24 2003-12-04 Angiotech International Ag Compositions and methods for coating medical implants
US8313760B2 (en) 2002-05-24 2012-11-20 Angiotech International Ag Compositions and methods for coating medical implants
CA2633589A1 (en) 2002-09-26 2004-04-08 Angiotech International Ag Perivascular wraps
EP1594459B1 (en) 2002-12-30 2010-02-17 Angiotech International Ag Drug delivery from rapid gelling polymer composition
US20040202666A1 (en) * 2003-01-24 2004-10-14 Immunomedics, Inc. Anti-cancer anthracycline drug-antibody conjugates
US20050043215A1 (en) 2003-02-19 2005-02-24 Tamara Minko Complex drug delivery composition and method for treating cancer
RU2361876C2 (ru) * 2003-04-22 2009-07-20 Сосьете Де Консей Де Решерш Э Д`Аппликасьон Сьентифик С.А.С. Пептидные векторы
AU2007221964B2 (en) * 2003-04-22 2008-12-11 Ipsen Pharma S.A.S. Peptide vectors
US7097993B2 (en) 2003-06-25 2006-08-29 Wisconsin Alumni Research Foundation Method for identifying an agent that modulates type 1 phosphatidylinositol phosphate kinase isoform β661 activity
US20080132458A1 (en) * 2004-03-10 2008-06-05 Threshold Pharmaceuticals, Inc. Hypoxia-Activated Anti-Cancer Agents
US20070060534A1 (en) * 2005-06-30 2007-03-15 Threshold Pharmaceuticals, Inc. Anthracycline analogs
JP5340155B2 (ja) * 2006-09-06 2013-11-13 エテルナ ツェンタリス ゲゼルシャフト ミット ベシュレンクテル ハフツング 細胞結合分子を有するジソラゾールのコンジュゲート及びそれらの誘導体、新規ジソラゾール誘導体、それらの製法ならびに使用
EP1900742A1 (en) 2006-09-07 2008-03-19 AEterna Zentaris GmbH Conjugates of disorazoles and their derivatives with cell-binding molecules, novel disorazole derivatives, processes of manufacturing and uses thereof
US20100087370A1 (en) * 2007-02-14 2010-04-08 The General Hospital Corporation Modulation of nitric oxide signaling to normalize tumor vasculature
ES2547552T3 (es) 2008-02-01 2015-10-07 Genentech, Inc. Metabolito de nemorrubicina y reactivos análogos, conjugados anticuerpo-fármaco y métodos
BRPI0911647A2 (pt) * 2008-04-11 2015-10-13 Tianjin Hemay Bio Tech Co Ltd compostos derivados de antibióticos de antraciclina com alta atividade, métodos de preeparação e uso dos mesmos.
WO2009124468A1 (zh) * 2008-04-11 2009-10-15 天津和美生物技术有限公司 具有高活性的四环蒽醌类抗生素的衍生物及其制备和应用
MX2011000509A (es) 2008-07-15 2011-04-05 Genentech Inc Conjugados derivados de antraciclina, proceso para su preparacion y su uso como compuestos antitumorales.
BRPI1008039A2 (pt) * 2009-02-20 2016-10-04 Ipsen Pharma Sas composto, mistura, composição farmacêutica, e, uso de um coposto, de uma mistura ou de uma composição farmacêutica
CN102050856B (zh) * 2009-11-03 2014-04-30 天津和美生物技术有限公司 具有高活性的表阿霉素的衍生物及其制备和应用
MX2013005972A (es) 2010-12-02 2013-08-09 Nerviano Medical Sciences Srl Proceso para la preparacion de derivados de morfolinil antraciclina.
CN105198966B (zh) * 2014-06-26 2019-06-21 中国人民解放军军事医学科学院毒物药物研究所 GnRH类似物-细胞毒分子缀合物、其制备方法及用途
EP3160518A4 (en) * 2014-06-30 2018-05-23 Tarveda Therapeutics, Inc. Targeted conjugates and particles and formulations thereof
EP3045540A1 (en) 2015-01-19 2016-07-20 Æterna Zentaris GmbH Enzymatic process for the regioselective manufacturing of N-Fmoc-doxorubicin-14-O-dicarboxylic acid mono esters
CA3001712A1 (en) 2015-10-28 2017-05-04 Tarveda Therapeutics, Inc. Sstr-targeted conjugates and particles and formulations thereof
US10450340B2 (en) 2017-02-16 2019-10-22 Monopar Therapeutics Inc. 3′-deamino-3′-(2″-pyrroline-1″-yl)-5-imino-13-deoxyanthracyclines and methods of preparation
WO2021068051A1 (en) * 2018-11-13 2021-04-15 Provincial Health Services Authority Radiolabeled bombesin-derived compounds for in vivo imaging of gastrin-releasing peptide receptor (grpr) and treatment of grpr-related disorders

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3725350A (en) * 1972-04-26 1973-04-03 Commercial Soluents Corp Polymeric substances comprising the reaction product of melamine, aldehyde and oxazolidines
US4299822A (en) * 1980-06-09 1981-11-10 Sidney Farber Cancer Institute, Inc. N-Trifluoroacetyladriamycin-14-O-hemiglutarate and -hemiadipate and therapeutic compositions containing same
US4464529A (en) * 1982-07-20 1984-08-07 Sri International Analogues of morpholinyl daunorubicin and morpholinyl doxorubicin
IL89220A (en) * 1988-02-11 1994-02-27 Bristol Myers Squibb Co Immunoconjugates of anthracycline, their production and pharmaceutical preparations containing them
US5217955A (en) * 1989-09-15 1993-06-08 Biomeasure, Inc. Treatment of cancer with peptide analog of bombesin, grp, litorin or neuromedin
US5304687A (en) * 1989-12-19 1994-04-19 Farmitalia Carlo Erba S.R.L. Morpholinyl derivatives of doxorubicin and process for their preparation
DK0434960T3 (da) * 1989-12-19 1996-10-14 Pharmacia Spa Chirale 1,5-diiod-2-methoxy- eller benzyloxymellemprodukter
ES2076393T3 (es) * 1990-04-06 1995-11-01 Univ Tulane Analogos de lhrh.
DK0450480T3 (da) * 1990-04-06 1995-08-14 Univ Tulane Somatostatinaloger
JP3169425B2 (ja) * 1992-03-27 2001-05-28 三共株式会社 アジドペンタンサイクリトール
US6214345B1 (en) * 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates

Also Published As

Publication number Publication date
CA2471775C (en) 2008-01-29
AU709539B2 (en) 1999-09-02
IS4734A (is) 1998-05-05
KR20040037176A (ko) 2004-05-04
KR19990071672A (ko) 1999-09-27
SK284672B6 (sk) 2005-08-04
BR9611647B1 (pt) 2010-03-09
WO1997019954A1 (en) 1997-06-05
AU7572296A (en) 1997-06-19
NO982252D0 (no) 1998-05-15
CA2471775A1 (en) 1997-06-05
IL119691A (en) 2002-02-10
CN1405127A (zh) 2003-03-26
IL134685A (en) 2002-12-01
IS2634B (is) 2010-06-15
JP4778405B2 (ja) 2011-09-21
ZA969709B (en) 1997-08-25
PL187230B1 (pl) 2004-06-30
IS8567A (is) 2006-11-09
NO324035B1 (no) 2007-07-30
JP2000502055A (ja) 2000-02-22
PT863917E (pt) 2004-02-27
CN1166597C (zh) 2004-09-15
CN1137136C (zh) 2004-02-04
HK1052920B (zh) 2005-03-04
JP3987575B2 (ja) 2007-10-10
DK1384710T3 (da) 2008-11-17
UA67722C2 (en) 2004-07-15
SK62898A3 (en) 1999-06-11
ATE251179T1 (de) 2003-10-15
CZ297297B6 (cs) 2006-11-15
EP0863917A1 (en) 1998-09-16
NO982252L (no) 1998-05-15
DK0863917T3 (da) 2004-01-19
EA001372B1 (ru) 2001-02-26
DE69637604D1 (de) 2008-08-28
DE69630233D1 (de) 2003-11-06
DE69630233T2 (de) 2004-08-05
CZ135798A3 (cs) 1998-10-14
ES2310222T3 (es) 2009-01-01
PL191781B1 (pl) 2006-07-31
ES2205067T3 (es) 2004-05-01
US5843903A (en) 1998-12-01
EP1384710B1 (en) 2008-07-16
IL134685A0 (en) 2001-04-30
EA199800492A1 (ru) 1998-12-24
IS2178B (is) 2006-12-15
CA2238574C (en) 2004-10-19
CA2238574A1 (en) 1997-06-05
PT1384710E (pt) 2008-10-08
NZ322054A (en) 1999-04-29
HU229870B1 (en) 2014-10-28
HK1052920A1 (en) 2003-10-03
CN1202903A (zh) 1998-12-23
IL119691A0 (en) 1997-02-18
PL188786B1 (pl) 2005-04-29
EP0863917B1 (en) 2003-10-01
HUP9903771A2 (hu) 2000-02-28
ATE401305T1 (de) 2008-08-15
KR100467899B1 (ko) 2005-01-24
MX9804119A (es) 1998-09-30
HK1017363A1 (en) 1999-11-19
NO20051111L (no) 2005-03-01
EP1384710A1 (en) 2004-01-28
HUP9903771A3 (en) 2000-07-28
US6184374B1 (en) 2001-02-06
BR9611647A (pt) 1999-02-23
KR100445754B1 (ko) 2004-12-08
JP2007045845A (ja) 2007-02-22
PL326865A1 (en) 1998-10-26

Similar Documents

Publication Publication Date Title
EP1384710B1 (en) Synthesis of heterocyclic compounds containing five- or six-membered rings
Nagy et al. Cytotoxic analogs of luteinizing hormone-releasing hormone containing doxorubicin or 2-pyrrolinodoxorubicin, a derivative 500-1000 times more potent.
Janaky et al. Analogues of luteinizing hormone-releasing hormone containing cytotoxic groups.
Russell-Jones et al. Synthesis of LHRH antagonists suitable for oral administration via the vitamin B12 uptake system.
US20120045393A1 (en) Lhrh-ii peptide analogs
JPH05505630A (ja) Ｌｈｒｈ拮抗薬
SK55193A3 (en) Bombesin antagonists
CZ20013318A3 (cs) Noví LH-RH-antagonisté se zlepąenými vlastnostmi rozpustnosti
HU208159B (en) Process for producing 1h-rh analogs and pharmaceutical compositions comprising same
AU748507B2 (en) Novel synthetic reaction and targeted cytotoxic anthracycline analogs obtained thereby
US20060100154A1 (en) Long-acting gonadotropin-releasing hormone analogs and methods of use thereof
UA76474C2 (en) Method for conversion of nitrogen of primary aminogroup - or --hydroxy of primary amine into nitrogen of monounsaturated compound
CZ200132A3 (cs) Podávači systém